UBS/CALL/IDORSIA/18.001/0.1/21.06.24 Stock

UBS/CALL/IDORSIA/18.001/0.1/21.06.24 Share Price

Warrant

FIDIGU

CH1170501840

Market Closed - Swiss Exchange 16:20:00 25/07/2023 BST
0.03 ^CHF	+50.00%

6 months

-93.18%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart IDORSIA LTD

Chart UBS/CALL/IDORSIA/18.001/0.1/21.06.24

Latest news about IDORSIA LTD

Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call	05-14	GL
Idorsia Secures Bondholders' Approval for Amendment to Terms of Outstanding Convertible Bonds	05-07	MT
Bondholders approve amended terms of the 2024 convertible bonds	05-06	GL
Idorsia Boosts Consent Fee Offer to 2024 Convertible Bond	05-02	MT

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	IDORSIA LTD
Issuer	UBS
	FIDIGU
ISIN	CH1170501840
Date issued	20/06/2022
Strike	18 CHF
Maturity	21/06/2024 (34 Days)
Parity	10 : 1
Emission price	0.38 CHF
Emission volume	N/A
Settlement	physical
Currency	CHF

Technical Indicators

Highest since issue	0.45 CHF
Lowest since issue	0.02 CHF

Company Profile

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Sector

More about the company